Usage and Dosing
Không cần chỉnh liều
Renal Adjustment
| Half-life bình thường | 1 |
|---|---|
| Half-life ESRD | 3–5 |
| Liều bình thường | 3–4 gm IV q4–6h |
| Chỉnh liều suy thận | CrCl >50: No dosage adjustment CrCl 30–50: 3–4 gm q6–8h CrCl 10–30: 3–4 gm q8h |
| Hemodialysis | 2 gm q8h (+ extra 1 gm AD) |
| CAPD | 3–4 gm q8h |
| CRRT | 3–4 gm q6–8h |
| SLED | No data |
Hepatic Adjustment
Không cần chỉnh liều
ECMO Dosing Adjustment
| Effect of ECMO | Minimal impact on drug PK |
|---|---|
| Dose recommendation | ECMO-specific dose adjustment not required |
| Comments, reference | Use non-ECMO ICU dosing strategies. Extended infusion (with therapeutic drug monitoring, if available) improves rate of target attainment. Ref: Clin Pharmacokinet 2026;65:193. |
Intraperitoneal Dosing Adjustment, CAPD
Không cần chỉnh liều
Obesity Dosing Adjustment
| Recommendation | 4.5 gm IV (over 4 hr) q6-8h |
|---|---|
| Comments | Suggested dosing in obesity particularly for critically ill patients, if MICs ≥8 µg/mL, or CrCl >100 mL/min (Pharmacotherapy 2023;43:226). |
Adverse Effects
Không cần chỉnh liều
Dược lý
Không cần chỉnh liều